OOPS- 3rd to market - Looks like Amgen messed up another PI - Prolia DejaVu

Anonymous

Guest
LOL - looks like Amgen still hasn't learned from the Prolia approval process and launch - what a shame. I'm guessing we harshly labeled our own new drug Repatha - High Risk or select patient types ....
 












I came here a few months ago from a solid pharma company w solid pipeline. My DM here left a month later. My main reason for coming was the excitement around Evo. Now that excitement is passing fast, and everything I believed about this being a different company has proved wrong. My resignation being turned in Friday. Thank goodness my old DM is among me back and had a position open. Live and learn.
 




LOL - looks like Amgen still hasn't learned from the Prolia approval process and launch - what a shame. I'm guessing we harshly labeled our own new drug Repatha - High Risk or select patient types ....

You really don't know what the fuck you're talking about. The 'PI" for these drugs will have a class indication until there is solid long term CV reduction data. And the 3rd to market makes no sense at all either.